Blood Res.  2023 Apr;58(S1):66-82. 10.5045/br.2023.2023023.

Mycosis fungoides and Sézary syndrome

• Lee H

• KMID: 2541985
• DOI: http://doi.org/10.5045/br.2023.2023023

Abstract

Mycosis fungoides (MF) and Sézary syndrome (SS) are a distinct disease entity of cutaneous T-cell lymphoma with heterogenous clinical features and prognosis. MF mainly involves skin and usually shows an indolent and favorable clinical course. In patients with advanced-stage disease, extracutaneous involvement including lymph nodes, viscera, and blood, or large cell transformation may be observed. SS is a leukemic form of advanced-stage MF, characterized by generalized erythroderma. Early-stage MF can be treated with skin-directed therapy. However, patients with refractory or advanced-stage disease are associated with severe symptoms or poor prognosis, requiring systemic therapy. Recent progress in understanding the pathogenesis of MF/SS has contributed to advances in the management of these rare diseases. This review aims to describe the clinical manifestations, diagnosis, risk stratification, and treatment strategy of MF/SS, focusing on the recent updates in the management of these diseases.

Keyword

Mycosis fungoides; Sézary syndrome; Cutaneous T-cell lymphoma; Diagnosis; Prognosis; Treatment